Fulcrum Therapeutics, Inc. (FULC) Financial Statements (2023 and earlier)

Company Profile

Business Address 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,09835,41257,05296,713
Cash and cash equivalents35,09835,41257,05296,713
Receivables2293,6372,531 
Other current assets   74284
Other undisclosed current assets172,192186,94959,8533,086
Total current assets:207,519225,998119,510100,083
Noncurrent Assets
Operating lease, right-of-use asset9,063   
Property, plant and equipment6,9067,3688,3979,205
Restricted cash and investments1,0921,0921,0921,092
Other noncurrent assets2,10554257859
Total noncurrent assets:19,1669,00210,06710,356
TOTAL ASSETS:226,685235,000129,577110,439
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,38410,7747,6725,785
Employee-related liabilities✕✕ 2,9282,239
Accounts payable3,6384,7884,0792,186
Accrued liabilities4,7465,9866651,360
Deferred revenue9344,71114,9103,989
Other liabilities105743849
Other undisclosed current liabilities7,3023,6404,1052,317
Total current liabilities:16,72519,19926,72512,140
Noncurrent Liabilities
Liabilities, other than long-term debt11,0181,6804,6207,625
Deferred revenue   2,9716,011
Deferred rent credit  1,6801,6491,559
Other liabilities197  55
Operating lease, liability10,821   
Other undisclosed noncurrent liabilities  2,5823,0513,521
Total noncurrent liabilities:11,0184,2627,67111,146
Total liabilities:27,74323,46134,39623,286
Equity
Equity, attributable to parent198,942211,53995,18187,153
Common stock52412823
Additional paid in capital612,025514,362316,775237,931
Accumulated other comprehensive loss(797)(397)(2) 
Accumulated deficit(412,338)(302,467)(221,620)(150,801)
Total equity:198,942211,53995,18187,153
TOTAL LIABILITIES AND EQUITY:226,685235,000129,577110,439

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues6,34219,1638,823 
Gross profit:6,34219,1638,823 
Operating expenses(118,903)(100,217)(80,434)(84,217)
Operating loss:(112,561)(81,054)(71,611)(84,217)
Nonoperating income
(Other Nonoperating income)		    29
Loss from continuing operations:(112,561)(81,054)(71,611)(84,188)
Loss before gain (loss) on sale of properties:✕✕(71,611)(84,188)
Other undisclosed net income2,6892077921,511
Net loss:(109,872)(80,847)(70,819)(82,677)
Other undisclosed net income attributable to parent1   
Net loss attributable to parent:(109,871)(80,847)(70,819)(82,677)
Preferred stock dividends and other adjustments    (7,128)
Net loss available to common stockholders, diluted:(109,871)(80,847)(70,819)(89,805)

Comprehensive Income ($ in thousands)
Annual | Quarterly

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(109,872)(80,847)(70,819)(82,677)
Other comprehensive loss(400)(395)(2) 
Comprehensive loss:(110,272)(81,242)(70,821)(82,677)
Other undisclosed comprehensive income, net of tax, attributable to parent1   
Comprehensive loss, net of tax, attributable to parent:(110,271)(81,242)(70,821)(82,677)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: